Member Info for Livedataaccount

There should also be an RNS for the firm placement shares?

Icecool.

I am simply going by the GANNT chart in the note. But hope you are correct and that patients are dosed in phase 2 this year.

Questions like.

The CEO made the most ridiculous statement of 'we are the beginning of the value curve'.?

I suggest a lot more question Avacta

Calm down, Timster. Only asking. You have over 18000 posts. Probably mostly on Avacta. Good to be transparent? You do have form for posting people's personal details on this forum.

Interestingly, Timster didn't want to answer whether he was taking part and deflected to wyndrum. Bit weird, considering. But then there has been a core of die hard Avactarians abusing anyone that has questioned Avacta. It's so important to question investments.

You taking part timmy?

I haven't. I thought I was clever and topped up just below a pound. I would take part if I could as there will be some big money getting in at this level. So expecting a pretty decent bounce from this level.

However, Avacta have lost a hell of a lot of trust in the market. Let's see how big the european fund is that took part, that the CEO has bigged up. One would hope there is a tr1 for their stake.

Phase 2 indications selected. Q3 of this year.

Expansion cohorts leading into pivotal Phase 2 study. Q4 2024.

Selection of FINAL phase 2 indication. Q2 2025

Icecool. no need for absuse. I realise this is all very frustrating and clear as mud, but thats my take from what Turner Pope has presented on the GANNT chart.

Icecool. It's there in the GANNT chart.

I admire your optimism, icecool and maybe I am totally missing something. But in the turner pope note there is a big red arrow on the GANNT chart that says q4 24 - dose expansion phase FOLLOWED on by P2.

Avacta have to come out and explain what exactly has gone on.

This is my gripe. They removed 1b and then re added it and just put it in the timeline as q4. Start dose expansion followed on by p2

The think shareholders are sick and tired of trying to decipher Avacta's change of strategy. Makes you wonder of they muddy the water on purpose. Complete mess.

In simplistic terms. Avacta still need to complete a phase 1b study (does expansion). Before P2 can begin. It's usual practice for a drug trial amd was their original plan.

According to the gant chart. Q424- expansion studies start LEADING in to Phase 2. You guys are expecting them to finish dose expansion studies in a quarter?

It's a UK listed company on the LSE AIM market going by their regulations. 40 day blackout. I don't buy

Bella, I will give you a sportsman's bet that P2 doesn't begin this year?

They still need to do the dose expansion phase.

Phase 2 will last 18 months?

This raise won't see Avacta through to keeping ava6000 in house. Far from it. Phase 2 s scheduled to begin h1 2025? This fund raise sees avacta through till end of 2025?

Obviously all of that could be subject to change. I take every update from Avacta with a bathful of salt